YK012 Clinical Trials

3 actively recruiting trials

No change since May 2026

Also known as: YK012 for Injection

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

Excyte Biopharma Ltd3

Indications

Cancer2
Systemic Lupus Erythematosus (SLE)1
Lupus1
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma1
B-cell Acute Lymphoblastic Leukemia1

Other3 trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Phase 1

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Phase 1/2

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.